REFERENCES
- Biederman, J., Melmed, R. D., Patel, A., McBurnett, R., Konow, J., Lyne, A. , for the SPD503 Study Group. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention deficit/hyperactivity disorder. Pediatrics, 121, e73–e84.
- Connor, D. F., Findling, R. L., Kollins, S. H., Sallee, F., López, F. A., Lyne, A., & Tremblay, G. (2010). Effects of guanfacine extended release on oppositional symptoms in children aged 6–12 years with attention-deficit hyperactivity disorder and oppositional symptoms: A randomized, double-blind, placebo-controlled trial. CNS Drugs, 24(9), 755–768. doi: 10.2165/11537790-000000000-00000
- Faraone, S. V., & Glatt, S. J. (2010). Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD. Journal of Attention Disorders, 13(5), 532–538.
- Jain, R., Segal, S., Kollins, S. H., & Khayrallah, M. (2011). Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 50, 171–179.
- Kasper, S., Olivieri, L., Di Loreto, G., & Dionisio, P. (2005). A comparative, randomized, double blind study of trazodone prolonged release and paroxetine in the treatment of patients with major depressive disorder. Current Medical Research and Opinion, 21(8), 1139–1146.
- The Medical Letter. (2011, February 7). Another extended-release α2-agonist for ADHD. The Medical Letter of Drugs and Therapeutics, 7(53), 10–12.
- Munizza, C., Olivieri, L., Di Loreto, G., & Dionisio, P. (2006). A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Current Medical Research and Opinion, 22(9), 1703–1713.
- Pub Med Health. (2011). Guanfacine. Retrieved from http: //www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000057
- Roman, M. W. (2011). Atypical antipsychotics: The two new arrivals. Issues in Mental Health Nursing, 32(1), 85–86.
- Scahill, L., Barloon, L., & Farkas, L. (1999). Psychopharmacology notes. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder. Journal of Child & Adolescent Psychiatric Nursing, 12(4), 168–173.
- Sheehan, D. V., Croft, H. A., Gossen, E. R., Levitt, R. J., & Brullé, C. (2009). Extended release trazodone in major depressive disorder: A randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont), 6(5), 20–33.
- Shire, USA (no date). Intuniv: highlights of prescribing information. Retrieved from http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf
- Shionogi. (2010). Highlights of Prescribing information. Retrieved August 6, 2011, from http://www.kapvay.com/Kapvay_final_09.28.10.pdf
- Spencer, T. J., Greenbaum, M., Ginsburg, L. D., & Murphy, W. R. (2009) Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 19(5), 501–510.
- Stahl, S. M. (2009). Essential psychopharmacology: Neuroscientific basis and practical implications (3rd ed.). Cambridge, UK: Cambridge University Press
- U.S. Department of Health and Human Services. (2011). What is comparative effectiveness research? Retrieved from http://www.effectivehealthcare.ahrq.gov/index.cfm/what-is-comparative-effectiveness-research1